SCHEMBL3597438

SCHEMBL3597438

N#Cc1c(-c2ccoc2)cc(-c2cccs2)nc1OCc1ccc(C(=O)O)cc1[N+](=O)[O-]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGES O14684 1/20 0.45
▸ KMT2A Q03164 7/20 0.42
▸ MEN1 O00255 6/20 0.40
▸ PABPC1 P11940 1/20 0.40
▸ PPP1CA P62136 1/20 0.40
▸ EIF4H Q15056 1/20 0.40
▸ SAE1 Q9UBE0 1/20 0.40
▸ UBA2 Q9UBT2 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ ALDH1A1 P00352 6/20 0.39
▸ HPGD P15428 4/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ NPSR1 Q6W5P4 3/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ KAT8 Q9H7Z6 1/20 0.38
▸ MAPT P10636 3/20 0.38
▸ GAA P10253 2/20 0.38
▸ GLA P06280 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ PDE5A O76074 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3597444 1.00 PTGES (0.45) PTGESKMT2AMEN1PABPC1PPP1CA
SCHEMBL3586484 0.92 ALDH1A1 (0.41) PTGESKMT2AMEN1PABPC1PPP1CA
SCHEMBL14391017 0.88 ALDH1A1 (0.46) KMT2AMEN1PABPC1PPP1CAEIF4H
SCHEMBL3590359 0.88 KMT2A (0.44) KMT2AMEN1PABPC1PPP1CAEIF4H
SCHEMBL3584550 0.88 KMT2A (0.44) KMT2AMEN1PABPC1PPP1CAEIF4H
SCHEMBL3580685 0.85 PDE5A (0.48) KMT2AMEN1PABPC1PPP1CAEIF4H
Tromethamine SCHEMBL3583622 0.84 KMT2A (0.42) KMT2AMEN1PABPC1PPP1CAEIF4H
Tromethamine SCHEMBL3598984 0.84 KMT2A (0.42) KMT2AMEN1PABPC1PPP1CAEIF4H
SCHEMBL3587275 0.83 KMT2A (0.46) KMT2AMEN1PABPC1PPP1CAEIF4H
SCHEMBL14390901 0.81 PTGES (0.38) PTGESKMT2AMEN1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009973-A1 Integrase Inhibitors 3 AVEXA LIMITED (AU) 2010-01-14 — — US disclosed
US-20100009973-A1 Integrase Inhibitors 3 AVEXA LIMITED (AU) 2010-01-14 — — US disclosed
EP-2019827-A1 INTEGRASE INHIBITORS 3 Avexa Limited (AU) 2009-02-04 — — EP disclosed
WO-2007124546-A1 INTEGRASE INHIBITORS 3 AVEXA LIMITED (AU) 2007-11-08 — — WO disclosed
WO-2007124546-A1 INTEGRASE INHIBITORS 3 AVEXA LIMITED (AU) 2007-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009973-A1 Integrase Inhibitors 3 TYMP, IMPDH1, IMPDH2 PTGES 4024/4885KMT2A 728/4885MEN1 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback